Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diabetology International
Published in: Diabetology International 3/2017

01-08-2017 | Original Article

Relationship between cardiovascular risk factors and hemorheology assessed by microchannel method in patients with type 2 diabetes mellitus

Author: Takashi Hitsumoto

Published in: Diabetology International | Issue 3/2017

Login to get access

Abstract

Aim

In addition to atherosclerosis, impairment of blood rheology is an important factor in cardiovascular events. The present study attempted to clarify the relationship between hemorheology and cardiovascular risk factors in patients with type 2 diabetes mellitus assessed by a microchannel method.

Methods

We enrolled 294 patients with type 2 diabetes mellitus (109 males and 185 females; mean age, 69 ± 11 years) with no history of cardiovascular events. Hemorheology was evaluated with a microchannel array flow analyzer, and the relationship between whole-blood passage time (WBPT) and various clinical parameters was examined.

Results

WBPT was significantly correlated with advanced glycation end-product (AGE) levels at the skin (r = 0.49, p < 0.001), serum reactive oxygen metabolite concentrations (oxidative stress markers) (r = 0.25, p < 0.001), the cardio-ankle vascular index (CAVI, arterial function marker) (r = 0.32, p < 0.001), and a number of classical cardiovascular risk factors in an individual (r = 0.45, p < 0.001). Multiple regression analysis revealed that these factors were selected as independent variables for WBPT as a subordinate factor.

Conclusion

Hemorheology is significantly associated with novel cardiovascular risk factors, such as AGEs, in vivo oxidative stress, and CAVI, and clustering of classical cardiovascular risk factors in patients with type 2 diabetes mellitus.
Literature
1.
Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GD, Fowkes FG. Relative value of inflammatory, hemostatic, and rheological factors for incident myocardial infarction and stroke: the Edinburgh Artery Study. Circulation. 2007;115:2119–27.CrossRefPubMed
2.
Matsuo K, Ueda Y, Nishio M, Hirata A, Asai M, Nemoto T, et al. Thrombogenic potential of whole blood is higher in patients with acute coronary syndrome than in patients with stable coronary diseases. Thromb Res. 2011;128:268–73.CrossRefPubMed
3.
Demirtunc R, Duman D, Basar M, Bilgi M, Teomete M, Garip T. The relationship between glycemic control and platelet activity in type 2 diabetes mellitus. J Diabetes Complicat. 2009;23:89–94.CrossRefPubMed
4.
Le Dévéhat C, Vimeux M, Khodabandehlou T. Blood rheology in patients with diabetes mellitus. Clin Hemorheol Microcirc. 2004;30:297–300.PubMed
5.
Kikuchi Y, Sato K, Mizuguchi Y. Modified cell flow microchannels in a single-crystal silicon substrate and flow behavior of blood cells. Microvasc Res. 1994;47:126–39.CrossRefPubMed
6.
Kurihara T, Deguchi S, Kato J, Furakawa M, Tsuchiya M, Akimoto M, et al. Impaired blood rheology by remnant-like lipoprotein particles: studies in patients with fatty liver disease. Clin Hemorheol Microcirc. 2001;24:217–25.PubMed
7.
Seki K, Sumino H, Nara M, Ishiyama N, Nishino M, Murakami M. Relationships between blood rheology and age, body mass index, blood cell count, fibrinogen, and lipids in healthy subjects. Clin Hemorheol Microcirc. 2006;34:401–10.PubMed
8.
Hitsumoto T. Factors affecting impairment of blood rheology in obese subjects. J Cardiol. 2012;60:401–6.CrossRefPubMed
9.
Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383–93.CrossRefPubMed
10.
Shinozaki K, Kashiwagi A, Nishio Y, Okamura T, Yoshida Y, Masada M, et al. Abnormal biopterin metabolism is a major cause of impaired endothelium-dependent relaxation through nitric oxide/O2-imbalance in insulin-resistant rat aorta. Diabetes. 1999;48:2437–45.CrossRefPubMed
11.
Lutgers HL, Graaff R, Links TP, Ubink-Veltmaat LJ, Bilo HJ, Gans RO, et al. Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes. Diabetes Care. 2006;29:2654–9.CrossRefPubMed
12.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.CrossRefPubMed
13.
Fridewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.
14.
Imai E, Horio M, Nitta K, Yamagata K, Iseki K, Hara S, et al. Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease. Clin Exp Nephrol. 2007;11:41–50.CrossRefPubMed
15.
Cearone MR, Belcaro G, Caratelli M, Cornelli U, DeSanctis MT, Incandela L, et al. A simple test to monitor oxidative stress. Int Angiol. 1999;18:127–30.
16.
Meerwaldt R, Hartog JW, Graaff R, Huisman RJ, Links TP, den Hollander NC, et al. Increased accumulation of skin advanced glycation end-products precedes and correlates with clinical manifestation of diabetic neuropathy. J Am Soc Nephrol. 2005;16:3687–93.CrossRefPubMed
17.
Nomoto K, Yagi M, Arita S, Hamada U, Yonei Y. A survey of fluorescence derived from advanced glycation end products in the skin of Japanese: differences with age and measurement location. Anti Aging Med. 2012;9:119–24.
18.
Shirai K, Utino J, Otsuka K, Takata M. A novel blood pressure-independent arterial wall stiffness parameter; cardio-ankle vascular index (CAVI). J Atheroscler Thromb. 2006;13:101–7.CrossRefPubMed
19.
Yoshida K, Kimura T, Aoki T, Tsunekawa K, Araki O, Shoho Y, et al. Fasting serum insulin levels and insulin resistance are associated with blood rheology in Japanese young adults without diabetes. J Int Med Res. 2016;44:496–507.CrossRefPubMed
20.
Yagi H, Sumino H, Aoki T, Tsunekawa K, Araki O, Kimura T, et al. Impaired blood rheology is associated with endothelial dysfunction in patients with coronary risk factors. Clin Hemorheol Microcirc. 2016;62:139–50.CrossRefPubMedPubMedCentral
21.
Bareford D, Jennings PE, Stone PC, Baar S, Barnett AH, Stuart J. Effects of hyperglycaemia and sorbitol accumulation on erythrocyte deformability in diabetes mellitus. J Clin Pathol. 1986;39:722–7.CrossRefPubMedPubMedCentral
22.
Demirtunc R, Duman D, Basar M, Bilgi M, Teomete M, Garip T. The relationship between glycemic control and platelet activity in type 2 diabetes mellitus. J Diabetes Complicat. 2009;23:89–94.CrossRefPubMed
23.
Meerwaldt R, Graaff R, Oomen PH, Links TP, Jager JJ, Alderson NL, et al. Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia. 2004;47:1324–30.CrossRefPubMed
24.
Morigi M, Angioletti S, Imberti B, Donadelli R, Micheletti G, Figliuzzi M, et al. Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-kB-dependent fashion. J Clin Invest. 1998;101:1905–15.CrossRefPubMedPubMedCentral
25.
Hasegawa Y, Suehiro A, Higasa S, Namba M, Kakishita E. Enhancing effect of advanced glycation end products on serotonin-induced platelet aggregation in patients with diabetes mellitus. Thromb Res. 2002;107:319–23.CrossRefPubMed
26.
Yamagishi S, Nakamura K, Imaizumi T. Advanced glycation end products (AGEs) and diabetic vascular complications. Curr Diabetes Rev. 2005;1:93–106.CrossRefPubMed
27.
Genevieve M, Vivot A, Gonzalez C, Raffaitin C, Barberger-Gateau P, Gin H, et al. Skin autofluorescence is associated with past glycaemic control and complications in type 1 diabetes mellitus. Diabetes Metab. 2013;39:349–54.CrossRefPubMed
28.
Facchini FS, Carantoni M, Jeppesen J, Reaven GM. Hematocrit and hemoglobin are independently related to insulin resistance and compensatory hyperinsulinemia in healthy, non-obese men and women. Metabolism. 1998;47:831–5.CrossRefPubMed
29.
Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes. 1999;48:1–9.CrossRefPubMed
30.
Forbes JM, Coughlan MT, Cooper ME. Oxidative stress as a major culprit in kidney disease in diabetes. J Int Med Res Diabetes. 2008;57:1446–54.
31.
Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GD, Fowkes FG. Inflammatory, haemostatic, and rheological markers for incident peripheral arterial disease: Edinburgh Artery Study. Eur Heart J. 2007;28:354–62.CrossRefPubMed
32.
Podrez EA, Byzova TV, Febbraio M, Salomon RG, Ma Y, Valiyaveettil M, et al. Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat Med. 2007;13:1086–95.CrossRefPubMedPubMedCentral
33.
Alam MA, Chowdhury MR, Jain P, Sagor MA, Reza HM. DPP-4 inhibitor sitagliptin prevents inflammation and oxidative stress of heart and kidney in two kidney and one clip (2K1C) rats. Diabetol Metab Syndr. 2015;7:107.CrossRefPubMedPubMedCentral
34.
Lodovici M, Bigagli E, Tarantini F, Di Serio C, Raimondi L. Losartan reduces oxidative damage to renal DNA and conserves plasma antioxidant capacity in diabetic rats. Exp Biol Med (Maywood). 2015;240:1500–4.CrossRefPubMedPubMedCentral
35.
Endo K, Miyashita Y, Sasaki H, Ebisuno M, Ohira M, Saiki A, et al. Probucol and atorvastatin decrease urinary 8-hydroxy-2′-deoxyguanosine in patients with diabetes and hypercholesterolemia. J Atheroscler Thromb. 2006;13:68–75.CrossRefPubMed
36.
Ott C, Raff U, Schmidt S, Kistner I, Friedrich S, Bramlage P, Harazny JM, et al. Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes. Cardiovasc Diabetol. 2014;13:19.CrossRefPubMedPubMedCentral
37.
Yamada K, Hirayama T, Hasegawa Y. Antiplatelet effect of losartan and telmisartan in patients with ischemic stroke. J Stroke Cerebrovasc Dis. 2007;16:225–31.CrossRefPubMed
38.
van der Loo B, Spring S, Koppensteiner R. High-dose atorvastatin treatment in patients with peripheral arterial disease: effects on platelet aggregation, blood rheology and plasma homocysteine. Clin Hemorheol Microcirc. 2011;47:241–51.PubMed
39.
Takahashi M, Shiba T, Hirano K, Hitsumoto T, Shirai K. Acute decrease of cardio-ankle vascular index with the administration of beraprost sodium. J Atheroscler Thromb. 2012;19:479–84.CrossRefPubMed
40.
Endo K, Saiki A, Ohira M, Miyashita Y, Shirai K. Cardio-ankle vascular index may reflect endothelial function in type 2 diabetes. Int J Clin Pract. 2011;65:1200–1.CrossRefPubMed
41.
Li Y, Tian XX, Liu T, Wang RT. Association between whole blood viscosity and arterial stiffness in patients with type 2 diabetes mellitus. Endocrine. 2015;49:148–54.CrossRefPubMed
42.
Shimada S, Hasegawa K, Wada H, Terashima S, Satoh-Asahara N, Yamakage H, et al. High blood viscosity is closely associated with cigarette smoking and markedly reduced by smoking cessation. Circ J. 2011;75:185–9.CrossRefPubMed
43.
Nakamura Y, Yamamoto T, Okamura T, Kadowaki T, Hayakawa T, Kita Y, et al. Combined cardiovascular risk factors and outcome: NIPPON DATA80, 1980–1994. Circ J. 2006;70:960–4.CrossRefPubMed
Metadata
Title
Relationship between cardiovascular risk factors and hemorheology assessed by microchannel method in patients with type 2 diabetes mellitus
Author
Takashi Hitsumoto
Publication date
01-08-2017
Publisher
Springer Japan
Published in
Diabetology International / Issue 3/2017
Print ISSN: 2190-1678
Electronic ISSN: 2190-1686
DOI
https://doi.org/10.1007/s13340-017-0314-2

Other articles of this Issue 3/2017

Diabetology International 3/2017 Go to the issue

Original Article

Quality of life in Japanese patients with type 1 diabetes and end-stage renal disease undergoing simultaneous pancreas and kidney transplantation

Original Article

Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes receiving conventional therapy: clinical implication of the importance of exercise habits during treatment with ipragliflozin

Original Article

Clinical features of cases of seroconversion of anti-glutamic acid decarboxylase antibody during the clinical course of type 2 diabetes: a nationwide survey in Japan

Commentary

Reprogramming of metabolism in immune-mediated cells

Erratum

Erratum to: Decreased glucagon levels and decreased insulin secretion after sitagliptin versus mitiglinide administration with similar glycemic levels following an oral glucose load: a randomized crossover pharmaceutical mechanistic study

Review Article

Immune regulation of glucose and lipid metabolism
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits